Notes
Incremental cost-effectiveness ratio
Reference
Mildred M. Is It All About Cost? a Re-Analysis of the Health Economic Evidence of First-Line Nilotinib in Patients with Cml. 18th Congress of the European Haematology Association : abstr. P509, 13 Jun 2013.
Rights and permissions
About this article
Cite this article
Nilotinib price discount influences positive recommendation. PharmacoEcon Outcomes News 682, 7 (2013). https://doi.org/10.1007/s40274-013-0541-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0541-0